Tirzepatide is administered as a once-weekly subcutaneous injection. The standard titration schedule increases the dose every 4 weeks to minimize gastrointestinal side effects.
Standard schedule: Week 1-4 at 2.5 mg, Week 5-8 at 5 mg, Week 9-12 at 7.5 mg, Week 13-16 at 10 mg, Week 17-20 at 12.5 mg, Week 21+ at 15 mg (maintenance). Each dose level is held for at least 4 weeks before considering escalation. The 2.5 mg starter dose is intended for tolerance only and is not therapeutic. Patients who tolerate well may reach maintenance at 20 weeks; patients who experience significant side effects may take longer or stay at a lower maintenance dose. Injection sites: abdomen, thigh, or upper arm — rotated weekly.
NexLife is structured around clinical best practices for tirzepatide. The same flat-rate pricing applies across the entire titration schedule ($186/mo on the 12-month plan from 2.5 mg through 15 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000